Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the successful completion of a substantial public offering of notes totaling $4.5 billion. The offering comprises four tranches with varying interest rates and maturity dates, ranging from 2031 to 2063. The company intends to utilize the net proceeds from this offering for general corporate purposes, with a specific mention of financing the proposed acquisition of Mirati Therapeutics, Inc., and associated fees and expenses. This issuance represents a strategic move to secure funding for significant future investments and operational needs. The notes are governed by an indenture, which includes customary covenants and restrictions related to incurring secured debt, engaging in sale/leaseback transactions, and significant corporate actions like mergers. The company retains the option to redeem the notes prior to maturity, with redemption terms outlined for both 'make-whole' provisions before a certain date and at par value on or after the applicable 'Par Call Date.' Investors should note the specific interest rates and maturity dates, as well as the company's flexibility in early redemption.
Key Highlights
- 1BMY successfully closed a $4.5 billion public offering of notes on November 13, 2023.
- 2The offering consists of four series of notes: $1B (5.750% due 2031), $1B (5.900% due 2033), $1.25B (6.250% due 2053), and $1.25B (6.400% due 2063).
- 3Proceeds are intended for general corporate purposes, notably to finance the proposed acquisition of Mirati Therapeutics, Inc.
- 4The notes are governed by an indenture with standard covenants and restrictions.
- 5Bristol-Myers Squibb has the option to redeem the notes before maturity, with specific provisions and pricing outlined.
- 6The offering was made pursuant to a prospectus supplement dated October 30, 2023.
- 7The report includes the underwriting agreement and supplemental indenture as filed exhibits.